Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MiMedx Group, Inc.
  6. Company
    MDXG   US6024961012

MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo MiMedx Group, Inc.
MiMedx Group, Inc. is utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing the needs of patients with acute and chronic non-healing wounds, and a late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. The CompanyÔÇÖs platform technologies include AmnioFix, EpiFix, EpiCord, AmnioCord and AmnioFill. Its AmnioFix and EpiFix are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. The EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. Its AmnioFill is a particulate product comprised of placental connective tissue matrix, derived from the placental disc and placental membranes.

Number of employees : 735 people.
Sales per Business
20192020Delta
Regenerative Biomaterials299.26100%248.23100% -17.05%
USD in Million
Sales per region
20192020Delta
United States299.26100%248.23100% -17.05%
USD in Million
Managers
Name Title Age Since
Timothy R. Wright Chief Executive Officer & Director 63 2019
Peter M. Carlson Chief Financial Officer 57 2020
David H. Mason, Dr. Chief Medical Officer 74 2018
Robert Stein Executive Vice President-Research & Development 70 2020
Scott M. Turner Vice President-Procurement 55 2016
Mark P. Graves Chief Compliance Officer & Senior VP 56 2018
James L. Bierman Independent Director 68 2019
M. Behrens Chairman 68 2019
K. Todd Newton Independent Director 58 2019
Martin P. Sutter Independent Director 66 2020
Members of the board
Name Title Age Since
M. Behrens Chairman 68 2019
Timothy R. Wright Chief Executive Officer & Director 63 2019
James L. Bierman Independent Director 68 2019
K. Todd Newton Independent Director 58 2019
Martin P. Sutter Independent Director 66 2020
William A. Hawkins Independent Director 67 2020
Michael J. Giuliani, Dr. Independent Director 66 2020
Phyllis I. Gardner, Dr. Independent Director 70 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 112,921,472 109,044,907 96.6% 777,028 0.7% 96.6%
Shareholders
NameEquities%
Essex Woodlands Management, Inc. 23,376,623 20.8%
Wellington Management Co. LLP 7,107,868 6.34%
Consonance Capital Management LP 5,990,682 5.34%
The Vanguard Group, Inc. 4,006,144 3.57%
Richard Jon Barry 3,338,135 2.98%
SSgA Funds Management, Inc. 3,285,588 2.93%
BlackRock Fund Advisors 2,545,037 2.27%
ClearBridge Investments LLC 2,202,120 1.96%
Lakewood Capital Management LP 1,851,109 1.65%
JPMorgan Asset Management (UK) Ltd. 1,790,713 1.60%
Company contact information
MiMedx Group, Inc.
1775 West Oak Commons Court NE
Marietta, GA 30062

Phone : +1.770.651.9100
Web : http://www.mimedx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of MiMedx Group, Inc.
Sector Biotechnology & Medical Research
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-29.30%474
GILEAD SCIENCES, INC.-7.35%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
MODERNA, INC.-41.48%62 828
VERTEX PHARMACEUTICALS3.93%57 608
LONZA GROUP AG-20.54%48 784
WUXI APPTEC CO., LTD.-12.95%47 873
IQVIA HOLDINGS INC.-17.77%44 443
BIONTECH SE-40.05%38 812
BEIGENE, LTD.-25.11%23 067
SEAGEN INC.-20.50%22 592
GENMAB A/S-16.31%21 833
ICON PUBLIC LIMITED COMPANY-18.28%20 601
CELLTRION, INC.-25.51%18 165
PPD, INC.38.16%16 614
INCYTE CORPORATION-2.47%16 240
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.-17.49%15 688
ALNYLAM PHARMACEUTICALS, INC.-25.00%15 563
BIO-TECHNE CORPORATION-31.60%14 296
PHARMARON BEIJING CO., LTD.-14.31%14 259
HANGZHOU TIGERMED CONSULTING CO., LTD-17.10%14 073